Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of gene expressions in epididymal white adipose tissue (eWAT) of genetic and diet-induced NASH model.

ABSTRACT: To investigate the alterlation of eWAT gene expression in diet-induced NASH model with adipose tissue insulin resistance, we evaluated eWAT of control mice and adipocyte-specific PDK1 knockout (PDK1KO) mice fed either normal chow(NC) or Gubra amylin NASH (GAN) diet for 16weeks after weaning at 4 weeks old. We then performed gene expression profiling analysis using data obtained from RNA-seq of these 4 groups.

ORGANISM(S): Mus musculus

PROVIDER: GSE224733 | GEO | 2023/02/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of adipose tissue insulin resistance on gene expression of liver in diet-induced NASH model.

Project description:To investigate the alterlation of liver gene expression in diet-induced NASH model with adipose tissue insulin resistance, we evaluated liver of control mice and adipocyte-specific PDK1 knockout (PDK1KO) mice fed either normal chow(NC) or Gubra amylin NASH (GAN) diet for 16weeks after weaning at 4 weeks old. We then performed gene expression profiling analysis using data obtained from RNA-seq of these 4 groups.

2022-11-09 | GSE216128 | GEO

Dietary intervention reverses molecular signatures of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Project description:We applied RNA sequencing (RNA-seq) to study the effects of dietary intervention on hallmarks of NASH and molecular signatures of hepatocellular senescence in the Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mouse model of NASH. GAN DIO-NASH mice with liver biopsy-confirmed NASH and fibrosis received dietary intervention by switching to chow feeding (chow reversal) for 8, 16, or 24 weeks. Untreated GAN DIO-NASH mice and chow-fed C57BL/6J mice served as controls. We find that chow reversal promoted substantial benefits on metabolic, biochemical and histological outcomes accompanied by marked suppression of gene expression markers of hepatocellular senescence in GAN DIO-NASH mice. These therapeutic benefits were reflected by progressive clearance of senescent hepatocellular cells, making the model suitable for profiling potential senotherapeutics in preclinical drug discovery for NASH.

2024-01-16 | GSE246328 | GEO

Bulk RNA sequencing of livers from Gubra-Amylin NASH diet fed Chrna2fl/fl and Chrna2fl/fl;Alb-Cre mice

Project description:Loss of Chrna2 in liver exacerbates development of Gubra-Amylin NASH diet induced non-alcoholic steatohepatitis.

2024-06-07 | GSE200595 | GEO

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Project description:Non-alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health because of high global prevalence and lack of evidence-based therapies. Most animal models of NASH lack sufficient validation regarding disease progression and pharmacological treatment. The Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mouse demonstrate clinical translatability with respect to disease etiology and hallmarks of NASH. This study aimed to evaluate disease progression and responsiveness to clinically effective interventions in GAN DIO-NASH mice. Disease phenotyping was performed in male C57BL/6J mice fed the GAN diet high in fat, fructose and cholesterol for 28-88 weeks. GAN DIO-NASH mice with biopsy-confirmed NASH and fibrosis received low-caloric dietary intervention, semaglutide (30 nmol/kg/day, s.c.) or lanifibranor (30 mg/kg/day, p.o.) for 8 and 12 weeks, respectively. Within-subject change in NAFLD Activity Score (NAS) and fibrosis stage was evaluated using automated deep learning-based image analysis. GAN DIO-NASH mice showed clear and reproducible progression in NASH, fibrosis stage and tumor burden with high incidence of hepatocellular carcinoma. Consistent with clinical trial outcomes, semaglutide and lanifibranor improved NAS, while only lanifibranor induced regression in fibrosis stage. Dietary intervention also demonstrated substantial benefits on metabolic outcomes and liver histology. Differential therapeutic efficacy of dietary intervention, semaglutide and lanifibranor was supported by quantitative histology, RNA sequencing, and blood/liver biochemistry. In conclusion, the GAN DIO-NASH mouse model recapitulates various histological stages of NASH and faithfully reproduces histological efficacy profiles of compounds in advanced clinical development for NASH. Collectively, these features highlight the utility of GAN DIO-NASH mice in preclinical drug development.

2022-02-21 | GSE196908 | GEO

Identification of a Broadly Fibrogenic Macrophage Subset Induced by Type 3 Inflammation

Project description:Cross-sectional single cell RNA sequencing (scRNAseq) of hepatic cells enzymatically isolated from murine models of toxin- (CCl4) or diet-induced (Gubra Amlyn Nash or GAN) liver fibrosis to identify macrophage populations associated with fibrosis.

2023-03-27 | GSE228232 | GEO

Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis

Project description:We applied RNA sequencing (RNA-seq) to study the gene expression profile in the liver of GAN DIO-NASH-HCC mice (non-tumorous tissue samples, n=9; tumor samples, n=9) and chow-fed controls (healthy liver samples, n=5)). Comparing tumour tissue of GAN DIO-NASH-HCC mice to healthy chow-fed controls, we find that tumors of GAN DIO-NASH-HCC mice show widespread regulations of genes associated with human HCC. Human HCC can be classified into three categories (S1-S3). Using the human S1-S3 gene classification described by Hoshida Y. et al. (2009), we find that GAN DIO-NASH-HCC tumors resemble the human S1 class of proliferating HCC tumors with poor prognosis.

2024-01-02 | GSE243976 | GEO

The eWAT proteomics of wild type mice and Mdm2 adipocyte-specific knock-in mice fed high-fat diet

Project description:The epididymal adipose tissue (eWAT) samples from wild type mice fed high-fat diet for 12 weeks (H_WT_E) and Mdm2 adipocyte-specific knock-in mice fed high-fat diet for 12 weeks (H_KI_E) were mixed separately, and subjected to proteomic study by Label-free quantitative techniques and mass spectrometry-based proteomics techniques, etc. The proteomics of mixed eWAT samples were performed in Jingjie PTM BioLab (Hangzhou) Co. Ltd (www.ptm-biolab.com.cn). The difference was determined by 1.5-fold-change criterion, FDR < 0.01.

2022-08-11 | PXD034074 | Pride

Profiling epididymal white adipose tissue (eWAT) from obese db/db and lean control db/+ mice

Project description:This program addresses the gene signature associated with the development of type 2 diabetes in the db/db mice. Specifically, which genes are differentially expressed in adipose tissue of the db/db mice compared to the control db/+ mice? The db/db mice eWAT profiling data was analyzed by identifying genes that were up- and down-regulated at selected p value and fold change in the eWAT of db/db mice compared to the corresponding db/+ controls.

2013-03-22 | E-GEOD-38082 | biostudies-arrayexpress

hMeDIP-seq profiling of DNA hydroxymethylation in primary adipocytes from epididymal white adipose tissue (eWAT) of adult C57BL/6J mice

Project description:DNA hydroxymethylation plays a crucial role in the regulation of gene transcription. In this study, using hMeDIP-seq experiment, we report the mapping of DNA hydroxymethylation in adipocytes from mouse eWAT Examination of DNA hydroxymethylation pattern in adipocytes from mouse eWAT

2014-10-02 | E-GEOD-57582 | biostudies-arrayexpress

NASH

Project description:Non-alcoholic fatty liver disease (NAFLD) is characterized by a series of pathological changes that can progress from simple fatty liver disease to non-alcoholic steatohepatitis (NASH). The objective of this study is to describe changes in global gene expression associated with the progression of NAFLD. This study is focused on the expression levels of genes responsible for the absorption, distribution, metabolism and excretion (ADME) of drugs. Differential gene expression between three clinically defined pathological groups; normal, steatosis and NASH was analyzed. The samples were diagnosed as normal, steatotic, NASH with fatty liver (NASH fatty) and NASH without fatty liver (NASH NF). Genome-wide mRNA levels in samples of human liver tissue were assayed with Affymetrix GeneChipM-. Human 1.0ST arrays

2011-07-12 | E-MEXP-3291 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data